-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
5-Fluorouracil-[6-d]
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/90344-84-6.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 90344-84-6 |
| Description | 5-Fluorouracil-d1 (5-FU-d1) is the deuterium labeled 5-Fluorouracil. It is an analogue of uracil and apotent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. |
Product Information
| Synonyms | 5-Fluorouracil-6-D1; 5-Fluoro-2,4(1H,3H)pyrimidinedione-d1; 2,4-Dihydroxy-5-fluoropyrimidine-d1; 5-FU-d1; 5-Fluoropyrimidine-2,4-diol-d1; Adrucil-d1; Arumel-d1; Carac-d1; Fluoroplex-d1; Fluorouracil-d1; Flurablastin-d1; Queroplex-d1; Timazin-d1; Ulup-d1 |
| IUPAC Name | 6-deuterio-5-fluoro-1H-pyrimidine-2,4-dione |
| Molecular Weight | 131.08 |
| Molecular Formula | C4H2DFN2O2 |
| Canonical SMILES | C1=C(C(=O)NC(=O)N1)F |
| InChI | InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)/i1D |
| InChIKey | GHASVSINZRGABV-MICDWDOJSA-N |
| Melting Point | 262-266°C |
| Purity | ≥98%; ≥99% atom D |
| Density | 1.55g/cm3 |
| Solubility | Slightly soluble in DMSO, Methanol |
| Appearance | White Solid |
| Application | Labelled 5-FU, a potent antineoplastic agent in clinical use. Also an inhibitor of DNA synthesis. |
| Storage | Store at 2-8°C |
| Complexity | 199 |
| Exact Mass | 130.01800 |
| Index Of Refraction | 1.523 |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
| PSA | 66.24000 |
| Target | Nucleoside Antimetabolite/Analog; HIV; Apoptosis; Endogenous Metabolite |
| XLogP3-AA | -0.9 |
